A PK/PD Study of CM4620-IE in Patients With Acute Pancreatitis
Status:
Completed
Trial end date:
2019-06-07
Target enrollment:
Participant gender:
Summary
This open-label study will evaluate the pharmacodynamic and pharmacokinetic profile of
CM4620-IE in patients with acute pancreatitis. The first five (5) patients will receive ≤
2.08 mg/kg of CM4620-IE by continuous IV infusion on Day 1. If necessary, up to an additional
4 patients may be treated at a different dose of CM4620-IE as determined by the obtained PK
and PD data. The infusion of CM4620-IE will start within 12 hours from the time the patient
or LAR provides informed consent.